Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Zura Bio Q4 EPS $(0.18) Beats $(0.25) Estimate; Cash Position Of $103.9M In Cash, Cash Equivalents And Investments Is Expected To Support Development And Operations Into 2026

Author: Benzinga Newsdesk | November 13, 2023 07:32am
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.25) by 28 percent. This is a 93.73 percent increase over losses of $(2.87) per share from the same period last year.

Posted In: ZURA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist